nach oben

Immunologic Research

Erschienen in:

02.05.2016 | Original Article

Vaccine delivery by penetratin: mechanism of antigen presentation by dendritic cells

verfasst von: Dodie Pouniotis, Choon-Kit Tang, Vasso Apostolopoulos, Geoffrey Pietersz

Erschienen in: Immunologic Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Cell-penetrating peptides (CPP) or membrane-translocating peptides such as penetratin from Antennapedia homeodomain or TAT from human immunodeficiency virus are useful vectors for the delivery of protein antigens or their cytotoxic (Tc) or helper (Th) T cell epitopes to antigen-presenting cells. Mice immunized with CPP containing immunogens elicit antigen-specific Tc and/or Th responses and could be protected from tumor challenges. In the present paper, we investigate the mechanism of class I and class II antigen presentation of ovalbumin covalently linked to penetratin (AntpOVA) by bone marrow-derived dendritic cells with the use of biochemical inhibitors of various pathways of antigen processing and presentation. Results from our study suggested that uptake of AntpOVA is via a combination of energy-independent (membrane fusion) and energy-dependent pathways (endocytosis). Once internalized by either mechanism, multiple tap-dependent or independent antigen presentation pathways are accessed while not completely dependent on proteasomal processing but involving proteolytic trimming in the ER and Golgi compartments. Our study provides an understanding on the mechanism of antigen presentation mediated by CPP and leads to greater insights into future development of vaccine formulations.

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11(9):509–24. doi:10.1038/nrclinonc.2014.111.CrossRefPubMed

Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr Opin Immunol. 2013;25(3):396–402. doi:10.1016/j.coi.2013.05.001.CrossRefPubMedPubMedCentral

Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv. 2013;2013:869718. doi:10.1155/2013/869718.CrossRefPubMedPubMedCentral

Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz GA, McKenzie IF, Apostolopoulos V. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy. 2013;5(11):1177–82. doi:10.2217/imt.13.126.CrossRefPubMed

Cohn L, Delamarre L. Dendritic cell-targeted vaccines. Front Immunol. 2014;5:255. doi:10.3389/fimmu.2014.00255.CrossRefPubMedPubMedCentral

Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Trans Med. 2014;6(232):232ra51. doi:10.1126/scitranslmed.3008068.CrossRef

Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines–hope or hype? Nat Rev Immunol. 2014;14(10):705–11. doi:10.1038/nri3727.CrossRefPubMed

Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J, et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(14):4844–53. doi:10.1158/1078-0432.CCR-11-0891.CrossRef

Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013;587(12):1693–702. doi:10.1016/j.febslet.2013.04.031.CrossRefPubMed

10.

Farkhani SM, Valizadeh A, Karami H, Mohammadi S, Sohrabi N, Badrzadeh F. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides. 2014;57:78–94. doi:10.1016/j.peptides.2014.04.015.CrossRefPubMed

11.

Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med. 2012;18(7):385–93. doi:10.1016/j.molmed.2012.04.012.CrossRefPubMed

12.

Wang F, Wang Y, Zhang X, Zhang W, Guo S, Jin F. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J Control Release Off J Control Release Soc. 2014;174:126–36. doi:10.1016/j.jconrel.2013.11.020.CrossRef

13.

Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA. Cell-penetrating peptides: application in vaccine delivery. Biochim Biophys Acta. 2010;1805(1):25–34. doi:10.1016/j.bbcan.2009.09.004.PubMed

14.

Apostolopoulos V, Pouniotis DS, van Maanen PJ, Andriessen RW, Lodding J, Xing PX, et al. Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine. 2006;24(16):3191–202. doi:10.1016/j.vaccine.2006.01.032.CrossRefPubMed

15.

Brooks NA, Pouniotis DS, Sheng KC, Apostolopoulos V, Pietersz GA. A membrane penetrating multiple antigen peptide (MAP) incorporating ovalbumin CD8 epitope induces potent immune responses in mice. Biochim Biophys Acta. 2010;1798(12):2286–95. doi:10.1016/j.bbamem.2010.05.007.CrossRefPubMed

16.

Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol. 2001;167(11):6462–70.CrossRefPubMed

17.

Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol. 1997;159(4):1666–8.PubMed

18.

Lu J, Higashimoto Y, Appella E, Celis E. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol. 2004;172(7):4575–82.CrossRefPubMed

19.

Pietersz GA, Li W, Apostolopoulos V. A 16-mer peptide (RQIKIWFQNRRMKWKK) from Antennapedia preferentially targets the Class I pathway. Vaccine. 2001;19(11–12):1397–405.CrossRefPubMed

20.

Pouniotis DS, Apostolopoulos V, Pietersz GA. Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology. 2006;117(3):329–39. doi:10.1111/j.1365-2567.2005.02304.x.CrossRefPubMedPubMedCentral

21.

Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways. Immunol Cell Biol. 2011;89(8):904–13. doi:10.1038/icb.2011.13.CrossRefPubMed

22.

Schutze-Redelmeier MP, Gournier H, Garcia-Pons F, Moussa M, Joliot AH, Volovitch M, et al. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. J Immunol. 1996;157(2):650–5.PubMed

23.

Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine. 2004;22(15–16):1985–91. doi:10.1016/j.vaccine.2003.10.028.CrossRefPubMed

24.

Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Investig. 2002;109(11):1463–70. doi:10.1172/JCI15399.CrossRefPubMedPubMedCentral

25.

Yang H, Cho NH, Seong SY. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours. Clin Exp Immunol. 2009;158(2):174–85. doi:10.1111/j.1365-2249.2009.03997.x.CrossRefPubMedPubMedCentral

26.

Yang Z, Wang L, Wang H, Shang X, Niu W, Li J, et al. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency. Mol Immunol. 2008;45(6):1674–81. doi:10.1016/j.molimm.2007.10.026.CrossRefPubMed

27.

Jiang Y, Li M, Zhang Z, Gong T, Sun X. Cell-penetrating peptides as delivery enhancers for vaccine. Curr Pharm Biotechnol. 2014;15(3):256–66.CrossRefPubMed

28.

Brooks N, Esparon S, Pouniotis D, Pietersz GA. Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides. Molecules. 2015;20(8):14033–50. doi:10.3390/molecules200814033.CrossRefPubMed

29.

Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol. 2011;23(1):12–20. doi:10.1016/j.smim.2011.01.001.CrossRefPubMed

30.

Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E. TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol. 2001;166(12):7063–71.CrossRefPubMed

31.

Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol. 2008;38(2):424–36. doi:10.1002/eji.200737578.CrossRefPubMed

32.

Sanderson S, Shastri N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol. 1994;6(3):369–76.CrossRefPubMed

33.

Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol. 2000;30(6):1714–23. doi:10.1002/1521-4141(200006)30:6<1714:AID-IMMU1714>3.0.CO;2-C.CrossRefPubMed

34.

Cho Y, Basta S, Chen W, Bennink JR, Yewdell JW. Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virus. J Virol. 2003;77(8):4679–84.CrossRefPubMedPubMedCentral

35.

Norbury CC, Princiotta MF, Bacik I, Brutkiewicz RR, Wood P, Elliott T, et al. Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo. J Immunol. 2001;166(7):4355–62.CrossRefPubMed

36.

Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem. 2003;278(1):585–90. doi:10.1074/jbc.M209548200.CrossRefPubMed

37.

Buhl T, Braun A, Forkel S, Mobius W, van Werven L, Jahn O, et al. Internalization routes of cell-penetrating melanoma antigen peptides into human dendritic cells. Exp Dermatol. 2014;23(1):20–6. doi:10.1111/exd.12285.CrossRefPubMed

38.

Potocky TB, Menon AK, Gellman SH. Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. J Biol Chem. 2003;278(50):50188–94. doi:10.1074/jbc.M308719200.CrossRefPubMed

39.

Sampath P, Pollard TD. Effects of cytochalasin, phalloidin, and pH on the elongation of actin filaments. Biochemistry. 1991;30(7):1973–80.CrossRefPubMed

40.

Lo WF, Dunn CD, Ong H, Metcalf ES, Soloski MJ. Bacterial and host factors involved in the major histocompatibility complex class Ib-restricted presentation of Salmonella Hsp 60: novel pathway. Infect Immun. 2004;72(5):2843–9.CrossRefPubMedPubMedCentral

41.

Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem. 2002;277(33):30208–18. doi:10.1074/jbc.M204202200.CrossRefPubMed

42.

Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim Biophys Acta. 2004;1665(1–2):48–56. doi:10.1016/j.bbamem.2004.06.022.CrossRefPubMed

43.

Schnitzer JE, Oh P, Pinney E, Allard J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J cell Biol. 1994;127(5):1217–32.CrossRefPubMed

44.

Pohl J, Ring A, Stremmel W. Uptake of long-chain fatty acids in HepG2 cells involves caveolae: analysis of a novel pathway. J Lipid Res. 2002;43(9):1390–9.CrossRefPubMed

45.

Orlandi PA, Fishman PH. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J Cell Biol. 1998;141(4):905–15.CrossRefPubMedPubMedCentral

46.

Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity. 1995;3(6):783–91.CrossRefPubMed

47.

Mellman I, Fuchs R, Helenius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem. 1986;55:663–700. doi:10.1146/annurev.bi.55.070186.003311.CrossRefPubMed

48.

Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 1995;267(5195):243–6.CrossRefPubMed

49.

West MA, Bretscher MS, Watts C. Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. J Cell Biol. 1989;109(6 Pt 1):2731–9.CrossRefPubMed

50.

Wileman T, Boshans RL, Schlesinger P, Stahl P. Monensin inhibits recycling of macrophage mannose-glycoprotein receptors and ligand delivery to lysosomes. Biochem J. 1984;220(3):665–75.CrossRefPubMedPubMedCentral

51.

Midoux P, Roche AC, Monsigny M. Quantitation of the binding, uptake, and degradation of fluoresceinylated neoglycoproteins by flow cytometry. Cytometry. 1987;8(3):327–34. doi:10.1002/cyto.990080314.CrossRefPubMed

52.

Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995;268(5211):726–31.CrossRefPubMed

53.

Umezawa H. Low-molecular-weight enzyme inhibitors of microbial origin. Annu Rev Microbiol. 1982;36:75–99. doi:10.1146/annurev.mi.36.100182.000451.CrossRefPubMed

54.

Kozlowski S, Corr M, Shirai M, Boyd LF, Pendleton CD, Berzofsky JA, et al. Multiple pathways are involved in the extracellular processing of MHC class I-restricted peptides. J Immunol. 1993;151(8):4033–44.PubMed

55.

Gil-Torregrosa BC. Raul Castano A, Del Val M. Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J Exp Med. 1998;188(6):1105–16.CrossRefPubMedPubMedCentral

56.

Delamarre L, Mellman I. Harnessing dendritic cells for immunotherapy. Semin Immunol. 2011;23(1):2–11. doi:10.1016/j.smim.2011.02.001.CrossRefPubMed

57.

Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443–73. doi:10.1146/annurev-immunol-032712-095910.CrossRefPubMedPubMedCentral

58.

Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–69. doi:10.1038/nri3254.CrossRefPubMed

59.

Gross BP, Wongrakpanich A, Francis MB, Salem AK, Norian LA. A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. AAPS J. 2014;16(6):1194–203. doi:10.1208/s12248-014-9662-z.CrossRefPubMedPubMedCentral

60.

Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer J Int Cancer. 2011;128(4):897–907. doi:10.1002/ijc.25399.CrossRef

61.

Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol. 2011;269(1):5–9. doi:10.1016/j.cellimm.2011.03.003.CrossRefPubMed

62.

Lenarczyk A, Le TT, Drane D, Malliaros J, Pearse M, Hamilton R, et al. ISCOM based vaccines for cancer immunotherapy. Vaccine. 2004;22(8):963–74.CrossRefPubMed

63.

Mansourian M, Badiee A, Jalali SA, Shariat S, Yazdani M, Amin M, et al. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunol Lett. 2014;162(1 Pt A):87–93. doi:10.1016/j.imlet.2014.07.008.CrossRefPubMed

64.

Cruz LJ, Rueda F, Simon L, Cordobilla B, Albericio F, Domingo JC. Liposomes containing NYESO1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines. Nanomedicine. 2014;9(4):435–49. doi:10.2217/NNM.13.66.CrossRefPubMed

65.

Park JS, Kim HS, Park HM, Kim CH, Kim TG. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model. Vaccine. 2011;29(47):8642–8. doi:10.1016/j.vaccine.2011.09.052.CrossRefPubMed

66.

Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol. 2002;168(5):2393–401.CrossRefPubMed

67.

Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008;1786(2):126–38. doi:10.1016/j.bbcan.2008.03.001.PubMed

68.

Wallbrecher R, Verdurmen WP, Schmidt S, Bovee-Geurts PH, Broecker F, Reinhardt A, et al. The stoichiometry of peptide-heparan sulfate binding as a determinant of uptake efficiency of cell-penetrating peptides. Cell Mol Life Sci CMLS. 2014;71(14):2717–29. doi:10.1007/s00018-013-1517-8.PubMed

69.

Wu X, Gehring W. Cellular uptake of the Antennapedia homeodomain polypeptide by macropinocytosis. Biochem Biophys Res Commun. 2014;443(4):1136–40. doi:10.1016/j.bbrc.2013.12.062.CrossRefPubMed

70.

Merzougui N, Kratzer R, Saveanu L, van Endert P. A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen. EMBO Rep. 2011;12(12):1257–64. doi:10.1038/embor.2011.203.CrossRefPubMedPubMedCentral

71.

Fehres CM, Unger WW, Garcia-Vallejo JJ, van Kooyk Y. Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol. 2014;5:149. doi:10.3389/fimmu.2014.00149.CrossRefPubMedPubMedCentral

Titel: Vaccine delivery by penetratin: mechanism of antigen presentation by dendritic cells
verfasst von: Dodie Pouniotis
Choon-Kit Tang
Vasso Apostolopoulos
Geoffrey Pietersz
Publikationsdatum: 02.05.2016
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 4/2016
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-016-8799-5

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Vaccine delivery by penetratin: mechanism of antigen presentation by dendritic cells

Abstract

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study

Cloning and characterizing of the murine IRF-3 gene promoter region

Association of HLA-G +3142 C>G polymorphism and breast cancer in Tunisian population

Fracture initiates systemic inflammatory response syndrome through recruiting polymorphonuclear leucocytes

Recombinant outer membrane protein C of Aeromonas hydrophila elicits mixed immune response and generates agglutinating antibodies

Generation of regulatory dendritic cells after treatment with paeoniflorin

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO